Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
601 questions in 75 reviews · Schizophrenia
current versionsNo studies 601 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Motivational interview plus oral health education vs Oral health education Adverse events: Clinically important specific adverse events · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane | No study reported useable data | 0 studies | No studies |
Oral health education (advice and training) vs Standard care (oral health advice not specifically emphasised beyond usual care) Oral health: Not having seen a dentist in the past year · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane | No study reported useable data | 0 studies | No studies |
Oral health education (advice and training) vs Standard care (oral health advice not specifically emphasised beyond usual care) Economic: Increased costs of health care · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane | no estimate extracted | 0 studies | No studies |
Motivational interview plus oral health education vs Oral health education Service use: Emergency medical/dental treatment · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane | No study reported useable data | 0 studies | No studies |
RISPERIDONE DEPOT vs PLACEBO Global state: Relapse ‐ long term ‐ not measured · patients with schizophrenia Risperidone (depot) for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE DEPOT vs PLACEBO Mental state: clinically significant improvement in mental state ‐ long term1 ‐ not reported · patients with schizophrenia Risperidone (depot) for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported · patients with schizophrenia Risperidone (depot) for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE Adverse effects: extrapyramidal ‐ short term · people with schizophrenia Risperidone versus placebo for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement in nutritional intake · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in measures of nutritional status: weight (kg), body mass index (kg/ m2), and waist/ hip ratio (cms) · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mental state · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically important adverse effects · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Measures of physiological function · participants with schizophrenia Dietary advice for people with schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Smoking cessation advice vs standard care Raised awareness of common problems associated with smoking · people with people with serious mental illness Smoking cessation advice for people with serious mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Smoking cessation advice vs standard care Reduction in smoking · people with people with serious mental illness Smoking cessation advice for people with serious mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Smoking cessation advice vs standard care Healthy days · people with people with serious mental illness Smoking cessation advice for people with serious mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Smoking cessation advice vs standard care Clinically important adverse effect · people with people with serious mental illness Smoking cessation advice for people with serious mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Smoking cessation advice vs standard care Economic outcome · people with people with serious mental illness Smoking cessation advice for people with serious mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
HALOPERIDOL vs OTHER ANTIPSYCHOTICS Specific behaviour: repeated need for tranquillisation · people with long‐term aggression in psychosis Haloperidol for long‐term aggression in psychosis (2016) · Cochrane | no estimate extracted | NR | No studies |
HALOPERIDOL vs OTHER ANTIPSYCHOTICS Adverse effects ‐ any serious, specific adverse effects · people with long‐term aggression in psychosis Haloperidol for long‐term aggression in psychosis (2016) · Cochrane | no estimate extracted | NR | No studies |
HALOPERIDOL vs OTHER ANTIPSYCHOTICS Economic outcomes · people with long‐term aggression in psychosis Haloperidol for long‐term aggression in psychosis (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs RISPERIDONE Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs RISPERIDONE Quality of life (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs RISPERIDONE Adverse effects: Extrapyramidal effects ‐ short/medium term (up to 12 weeks) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs RISPERIDONE Cost‐effectiveness (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs QUETIAPINE Relapse (long term) · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs QUETIAPINE Clinically important change in life skills (long term) · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs QUETIAPINE Quality of life (long term) · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs QUETIAPINE Adverse effects: Extrapyramidal effects ‐ short/medium term (up to 12 weeks) · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs AMISULPRIDE Relapse (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs QUETIAPINE Cost‐effectiveness (long term) · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs OLANZAPINE Relapse (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs OLANZAPINE Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs OLANZAPINE Quality of life (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs OLANZAPINE Cost‐effectiveness (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs AMISULPRIDE Clinically important change in life skills (long term) ‐ not measured · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs AMISULPRIDE Quality of life (long term) ‐ not measured · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs AMISULPRIDE Cost‐effectiveness (long term) ‐ not measured · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) vs RISPERIDONE Relapse (long term) ‐ not reported · patients with schizophrenia Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinical improvement in pulse rate · adults with schizophrenia or related disorders treated for clozapine‐induced tachycardia Pharmacological interventions for clozapine‐induced sinus tachycardia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement in heart rate · adults with schizophrenia or related disorders treated for clozapine‐induced tachycardia Pharmacological interventions for clozapine‐induced sinus tachycardia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Duration of hospitalisation · adults with schizophrenia or related disorders treated for clozapine‐induced tachycardia Pharmacological interventions for clozapine‐induced sinus tachycardia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Clinically important adverse events · adults with schizophrenia or related disorders treated for clozapine‐induced tachycardia Pharmacological interventions for clozapine‐induced sinus tachycardia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient satisfaction · adults with schizophrenia or related disorders treated for clozapine‐induced tachycardia Pharmacological interventions for clozapine‐induced sinus tachycardia (2016) · Cochrane | no estimate extracted | NR | No studies |
Oral health education (advice and training) vs Standard care (oral health advice not specifically emphasised beyond usual care) Quality of life: Chronic pain · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane | No study reported useable data | 0 studies | No studies |
Motivational interview plus oral health education vs Oral health education Oral health: Not brushing teeth twice a day · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane | No study reported useable data | 0 studies | No studies |
Motivational interview plus oral health education vs Oral health education Oral health: Not having seen a dentist in the past year · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane | No study reported useable data | 0 studies | No studies |
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Hospital admission ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Death ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Clinically significant change in global state ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane | no estimate extracted | NR | No studies |